Healthcare / BiotechnologyNasdaqGS
$17.06
-1.11 (-6.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-119.8M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-156.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-2073.5%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.0M · net income $-377.7M · FCF $-207.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.0M | $10.0M | $5.0M | $50.0M | — |
| Net Income | $-377.7M | $-377.7M | $-157.0M | $-37.1M | $-119.3M |
| EBITDA | $-370.4M | $-370.4M | $-156.4M | $-27.0M | $-75.1M |
| EPS | — | — | -11.89 | -2.13 | -9.26 |
| Operating Margin | -2113.8% | -2113.8% | -3277.8% | -54.3% | — |
| Net Margin | -3777.4% | -3777.4% | -3139.8% | -74.2% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | -0.09 | -0.01 |
| Current Ratio | 11.94 | 11.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-207.4M | $-207.4M | $-119.8M | $-30.5M | $-67.8M |
| Returns | |||||
| ROE | -156.0% | -156.0% | -50.2% | 16.4% | 62.0% |
| Valuation | |||||
| P/B | 3.84 | 3.84 | 0.42 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 100.0% | 100.0% | -90.0% | — | — |
| EPS Growth | — | — | -457.8% | 77.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+69.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-11.89 → n/d
Residual
+69.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.